Synthesis of Novel 4-Chloro-5-methyl-2-(R-thio)-N-(2,3-dihydro-1,3,4-thiadiazol-2-ylidene)benzenesulfonamide Derivatives

• Autorzy: Sławiński J.
• Języki publikacji: EN

Abstrakty

EN

Two series of novel 4-chloro-5-methyl-2-(R-thio)-N-(2,3-dihydro-1,3,4-thiadiazol-2- ylidene)benzenesulfonamide derivatives 5-14 were synthesized by the reaction of potassium 6-chloro-1,1-dioxo-7-methyl-1,4,2-benzodithiazine-3-thiolate (1) or 6-chloro-3- mercapto-7-methyl-1,4,2-benzodithiazine 1,1-dioxide (2) with hydrazonyl bromides 3a-g. Suggested mechanisms of the investigated reaction were discussed. Themolecular orbital calculation of the possible tautomeric forms of 3-mercaptobenzodithiazine 2 were also presented.

Słowa kluczowe

EN

4-chloro-5-methyl-2-(R-thio)-N-(2,3-dihydro-1,3,4-thiadiazol-2-ylidene) benzenesulfonamides; synthesis

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2006
• Tom: Vol. 80, nr 9
• Strony: 1503--1511
• Opis fizyczny: Bibliogr. 41 poz., rys.

Twórcy

autor

Sławiński J.

• Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland

Bibliografia

• 1. Casini A., Scozzafava A., Mastrolorenzo A. and Supuran C.T., Curr. Cancer Drug Targets, 2,55 (2002).
• 2. Scozzafava A., Owa T., Mastrolorenzo A. and Supuran C.T., Curr. Med. Chem., 10, 925 (2003).
• 3. Supuran C.T., Casini A. and Scozzafava A., Med. Res. Rev., 23, 535 (2003).
• 4. Sławiński J., Bednarski P, Griinert R. and Reszka P., Polish J. Chem., 77, 53 (2003).
• 5. Brzozowski Z., Sączewski F. and Gdaniec M., Eur. J. Med. Chem., 38, 991 (2003).
• 6. Brzozowski Z., Sączewski F. and Gdaniec M., Bioorg. Med. Chem., 11, 3673 (2003).
• 7. Sławiński J., Bednarski P. and Reszka R, Polish J. Chem., 78, 369 (2004).
• 8. Sławiński J., Eur. J. Med. Chem., 39, 179 (2004).
• 9. Sławiński J. and Gdaniec M., Eur. J. Med. Chem., 40, 377 (2005).
• 10.Brzozowski Z., Sławiński J., Kosmala M., Olędzka K., Filczewski M., Miłobędzka J. and Lewandowski K., Acta Polon. Pharm. Drug Res., 48, 39 (1991).
• 11.Brzozowski Z., Sławiński J., Olędzka K., Kosmala M., Lewandowski K., Filczewski M. and Miłobędzka J., Acta Polon. Pharm. Drug Res., 50, 353 (1993).
• 12.Brzozowski Z., Acta Polon. Pharm. Drug Res., 52, 91 (1995).
• 13.Brzozowski Z., Acta Polon. Pharm. Drug Res., 53, 269 (1996).
• 14.Pomarnacka E. and Kozlarska-Kedra L, Farmaco, 58, 423 (2003).
• 15.Pomarnacka E., Acta Polon. Pharm. Drug Res., 53, 373 (1996).
• 16.Pomarnacka E. and Brzozowski Z., Acta Polon. Pharm. Drug Res., 54, 215 (1997).
• 17.Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 375 (1998).
• 18.Pomarnacka E. and Kornicka A., Farmaco, 56, 571 (2001).
• 19.Pomarnacka E., Acta Polon. Pharm. Drug Res., 55, 481 (1998).
• 20.Brzozowski Z. and Kornicka A., Acta Polon. Pharm. Drug Res., 56, 135 (1999).
• 21.Brzozowski Z., Sączewski F. and Gdaniec M., Eur. J. Med. Chem., 37, 285 (2002).
• 22.Brzozowski Z., Acta Polon. Pharm. Drug Res., 52, 287 (1995).
• 23.Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 49 (1998).
• 24.Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 473 (1998).
• 25.Neamati N., Mazumder A., Sunder S., Owen J.M., SchultzR.J., Pommier Y.,Antivir. Chem. Chemother., 8,485(1997).
• 26.Kuo Ch.L., Assefa H., Kamath S., Brzozowski Z., Sławiński J., Sączewski F., Buolamwini J.K. and Neamati N., J. Med. Chem., 47, 385 (2004).
• 27.Brzozowski Z. and Sławiński J., Acta Polon. Pharm. Drug Res., 49 (4), 85 (1992).
• 28.Brzozowski Z. and Sławiński J., Acta Polon. Pharm. Drug Res., 49 (5), 81 (1992).
• 29.Brzozowski Z., Sławiński J., Borowik W. and Gajewski F., Acta Polon. Pharm. Drug Res., 49,93 (1992).
• 30.Shawali A.S., Chem. Rev„ 93, 2731 (1993).
• 31.Padwa A.,Angew. Chem. Int. Ed. Engl., 15, 123 (1976).
• 32.Huisgen R., Ustman R.S. and Wallbillich G., Chem. Ber., 100, 1787 (1976).
• 33.Abdelhamid A.O. and Attaby F.A., J. Heterocyclic Chem. 28, 41 (1991).
• 34.Wolkoff P. and Hammerum S., Acta Chem. Scand. B, 30, 837 (1976).
• 35.Dickore K. and Waglen R., Angew. Chem. Int. Ed. Engl., 5, 970 (1966).
• 36.Abdelhamid A.O., Abbas I.M., Abdallah M.A., Fahmi A.A. and Shawali A.S., J. Heterocyclic Chem., 22,813(1985).
• 37.Kornis G., Comprehensive Heterocyclic Chemistry, Pergamon Press Ltd., NY 1984, vol. 6, p. 549.
• 38.The geometries of 2 and the tautomeric structures 2A and 2B were fully optimized in vacuo using a molecular orbital ab initio method at the Hartree-Fock level with the 6-31 G** basis set. The calculations were carried out using the Spartan Pro program version l ,0,5 (2000), distributed by Wavefunction Inc.
• 39.Brzozowski Z. and Sławiński J., Acta Polon. Pharm., 41, 133 (1984).
• 40.Heagarty A.F., Cashman M.P. and Scott F.L., J. Chem. Soc. Perkin Trans. II, 1381 (1972).
• 41.Aylward J.B. and Scott F.L., J. Chem. Soc. B, 1080 (1969).